You are here

  • Home
  • Archive
  • Volume 10, Issue 8
  • Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors

Authors

  • Hemanth K Potluri University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA PubMed articlesGoogle scholar articles
  • Carolina A Ferreira University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USAMedical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA PubMed articlesGoogle scholar articles
  • Joseph Grudzinski University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USARadiology, University of Wisconsin-Madison, Madison, Wisconsin, USA PubMed articlesGoogle scholar articles
  • Christopher Massey University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USARadiology, University of Wisconsin-Madison, Madison, Wisconsin, USA PubMed articlesGoogle scholar articles
  • Eduardo Aluicio-Sarduy Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA PubMed articlesGoogle scholar articles
  • Jonathan W Engle Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USARadiology, University of Wisconsin-Madison, Madison, Wisconsin, USA PubMed articlesGoogle scholar articles
  • Ohyun Kwon University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USAMedical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA PubMed articlesGoogle scholar articles
  • Ian R Marsh University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USAMedical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USARadiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  • Bryan P Bednarz University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USAMedical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA PubMed articlesGoogle scholar articles
  • Reinier Hernandez University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USAMedical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA PubMed articlesGoogle scholar articles
  • Jamey P Weichert University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USARadiology, University of Wisconsin-Madison, Madison, Wisconsin, USA PubMed articlesGoogle scholar articles
  • Douglas G McNeel University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Douglas G McNeel; dm3{at}medicine.wisc.edu
View Full Text

Citation

Potluri HK, Ferreira CA, Grudzinski J, et al
Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors
Journal for ImmunoTherapy of Cancer 2022;10:e005060. doi: 10.1136/jitc-2022-005060

Publication history

  • Accepted July 23, 2022
  • First published August 24, 2022.
Online issue publication 
November 15, 2022

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.